Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Long-Term Outcomes of CAR T-Cell Therapy for Patients With Relapsed/Refractory CLL

06/21/2023

Emily C. Liang , MD;

At the 2023 ASCO annual meeting, Emily C. Liang, MD, shared data on the long-term outcomes of patients with relapsed/refractory chronic lymphocytic leukemia treated with CD19-targeting CAR T-cell therapy.

At the 2023 ASCO annual meeting,...

06/21/2023

Oncology

Q&As

Ibrutinib Combined With Obinutuzumab and Venetoclax for the Frontline Treatment of Older Patients With CLL

06/19/2023

Jennifer Ann Woyach , MD;

At the 2023 ASCO annual meeting, Jennifer Ann Woyach, MD, shared data on ibrutinib combined with obinutuzumab and venetoclax vs ibrutinib plus obinutuzumab for the frontline treatment of older patients with CLL in the setting of the COVID-19...

At the 2023 ASCO annual meeting,...

06/19/2023

Oncology

Sponsored

Videos

Chronic Lymphocytic Leukemia: A Review of Unmet Needs in Prognostic Biomarker Testing

06/07/2023

M. Yair Levy, MD, Texas Oncology, discusses the importance of biomarker testing for patients with CLL, reviews unmet needs in prognostic biomarker testing and selection of therapies, and outlines clinical practice guidelines for high-risk...

M. Yair Levy, MD, Texas...

06/07/2023

Oncology

Videos

Treating a Patient With Unmutated IGHV, ATM-Deleted Chronic Lymphocytic Leukemia

03/27/2023

Talha Munir, MD, St. James's Hospital in Leeds, United Kingdom, highlights his treatment choices for the case of a 76-year-old patient with chronic lymphocytic leukemia.

Talha Munir, MD, St. James's...

03/27/2023

Oncology

Videos

Early MRD Clearance With Ibrutinib Plus Venetoclax Yields Sustained Clinical and MRD Responses in CLL

01/26/2023

Talha Munir, MD, discusses findings from an exploratory analysis of the phase 2 CLARITY trial, which showed that early MRD clearance with ibrutinib plus venetoclax yields sustained clinical and MRD responses in relapsed/refractory CLL.

Talha Munir, MD, discusses...

01/26/2023

Oncology

Videos

Ibrutinib Plus Venetoclax Induces High Rates of MRD Negativity in IGHV-Unmutated CLL

01/16/2023

Talha Munir, MD, discusses findings from an updated interim analysis of the FLAIR study at the 2022 ASH Annual Meeting & Exposition in New Orleans, LA.

Talha Munir, MD, discusses...

01/16/2023

Oncology

Videos

Role of Minimal Residual Disease in the Management of CLL: How Do We Use it and When?

11/15/2022

Othman Al-Sawaf, MD, provides insight into the best use of minimal residual disease in the management of patients with CLL, which he presented at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Othman Al-Sawaf, MD, provides...

11/15/2022

Oncology

Videos

BTK Inhibitors vs BCL-2 Inhibitors as Frontline Therapy for Patients With CLL

11/14/2022

Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Asher Chanan-Khan, MD, argues in...

11/14/2022

Oncology

Videos

New and Emerging Targeted Agents for CLL: A Review of Available BTK Inhibitors

11/14/2022

Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.

Jan Burger, MD, discusses...

11/14/2022

Oncology

Anthony Mato, MD, PhD, Memorial Sloan Kettering Cancer Center

Videos

Impact of Venetoclax Discontinuation or Modification on Survival Outcomes Among Patients With CLL

06/28/2022

Anthony Mato, MD, PhD, highlights findings from a post-hoc analysis of the phase 3 MURANO trial, which explored the impact of venetoclax dose modification and early discontinuation on survival outcomes for patients with CLL.

Anthony Mato, MD, PhD,...

06/28/2022

Oncology

Chronic Lymphocytic Leukemia Excellence Forum

Specialties

Events

Year Round Education

HMP Global Products